Drug Profile
HTC 867
Alternative Names: HTC-867Latest Information Update: 26 Sep 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Antipsychotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders
Most Recent Events
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 31 Jan 2009 Phase-I clinical trials in Cognition disorders in USA (PO)
- 16 Oct 2008 Phase-0 for Cognition disorders in USA (PO)